🔎 Trials Near Me

Akèy › Sistèm Imunitè ak Twoub › Pennsylvania

Etid klinik pou Sistèm Imunitè ak Twoub nan Pennsylvania

12 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan Pennsylvania.

Vil nan Pennsylvania

Tèks ofisyèl etid la (Anglè)

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • University of Pennsylvania - Abramson Cancer Center, Philadelphia
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07192471

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
  • Lewis Katz School of Medicine at Temple University, Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06722235

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Christiana Care Health System-Concord Health Center, Chadds Ford
  • ak 18 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 17, 2026 · NCT04242095

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
  • Lewis Katz School of Medicine at Temple University, Philadelphia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06948318

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Lehigh Valley Topper Cancer Center Institute, Allentown
  • Thomas Jefferson University, Philadelphia
  • West Penn Hospital, Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535

Abatacept for the Treatment of Giant Cell Arteritis

  • University of Pennsylvania, Philadelphia
Ap rekriteFaz 3
Laj 50 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT04474847

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

  • UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT04658303

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

  • Children's Hospital of Philadelphia, Philadelphia
Ap rekriteFaz 2
Tout laj · Tout sèks · Mizajou Jun 2, 2026 · NCT05787574

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • UPMC Hilman Cancer Center, Pittsburgh
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

  • UPMC Hillman Cancer Center, Pittsburgh
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 15, 2025 · NCT06619561

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.